Benchmark International 
Archives
M&A in the Biotech sector rose by 25 per cent in the third quarter of 2016 compared to the two previous quarters, but is still down in activity seen in 2015. This activity was driven by small and medium deals but also the biggest deal of the year so far; German drug manufacturer Bayer’s takeover of the US agricultural seed producer, Monsanto, for $66 billion. August was a period of buyer’s remorse,… Read More
Think healthcare M&A is on its way out in 2016? Think again. Following the surprising failure in April of the deal between Pfizer and Allergan, many analysts have raised concerns that a similar pattern will ensue within healthcare deal making. While the collapse of the $160bn deal was unexpected, and brought total value of abandoned deals this year to its highest since the eve of the financial crisis at $376bn, industry experts… Read More